Simplifying Global Compliance
Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review
Affymax surged the most in the 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen and Johnson & Johnson for chronic kidney disease.
Copyright ©2014. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing